Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its earnings results on Tuesday, August, 8th. The company reported $1.72 EPS for the quarter, missing the Zacks' consensus estimate of $1.85 by $0.13. The company earned $394.39 million during the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company's quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.67 EPS. View Jazz Pharmaceuticals PLC's Earnings History.

Jazz Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC updated its FY17 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.02. The company issued revenue guidance of $1.625-1.7 billion, compared to the consensus revenue estimate of $1.66 billion.

19 brokerages have issued 12-month price objectives for Jazz Pharmaceuticals PLC's shares. Their forecasts range from $144.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's share price to reach $182.84 in the next year. View Analyst Ratings for Jazz Pharmaceuticals PLC.

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

• 1. According to Zacks Investment Research, "Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release." (8/8/2017)
• 2. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
• 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
• 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
• 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Jazz Pharmaceuticals PLC saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,492,906 shares, an increase of 39.2% from the August 15th total of 1,790,242 shares. Based on an average trading volume of 533,555 shares, the short-interest ratio is presently 4.7 days. Approximately 4.3% of the shares of the company are short sold.

Some companies that are related to Jazz Pharmaceuticals PLC include Grifols, S.A. (GRFS), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), XOMA Corporation (XOMA), VBI Vaccines (VBIV), Concordia International Corp (CXR), Protalix Biotherapeutics (PLX), ContraFect Corporation (CFRX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF) and Soligenix (SNGX).

Jazz Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (13.81%), Vanguard Group Inc. (7.79%), BlackRock Inc. (5.18%), JPMorgan Chase & Co. (2.34%), Bank of New York Mellon Corp (2.30%) and Westfield Capital Management Co. LP (2.20%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, BlackRock Inc., Nomura Holdings Inc., Bank of New York Mellon Corp, Tekla Capital Management LLC, Westfield Capital Management Co. LP, Gateway Investment Advisers LLC and State Street Corp. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, JPMorgan Chase & Co., American Century Companies Inc., Zurcher Kantonalbank Zurich Cantonalbank, Balyasny Asset Management LLC, Vanguard Group Inc. and Pioneer Investment Management Inc.. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $147.89.